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Mutations in the eukaryotic translation initiation factor 4-gamma (EIF4G1) gene, 
encoding a component of the eIF4F translation initiation complex, were recently reported as a 
possible cause for autosomal dominant (AD) form of Parkinson’s disease (PD). Here, we 
describe the screening of all 31 EIF4G1 coding exons in a series of 251 index cases with AD 
PD, mostly of French origin and in 236 European control subjects. We identified 12 rare 
coding variants (either non-synonymous amino-acid substitutions or in frame deletions/ 
insertions), including six variants present only in cases and three in controls. Segregation was 
possible only for one variant (p.E462delInsGK) that was found in two affected siblings. In 
addition, we found two previously reported pathogenic variants in two isolated patients 
(p.G686C) and in a control subject (p.R1197W). These data do not support the pathogenicity 
of several EIF4G1 variants in PD, at least in the French population. 
 




The first causal mutation for Parkinson’s disease (PD) was identified in 1997, in the 
gene SNCA/PARK1. Two other genes [Leucine-rich repeat kinase 2 (LRRK2)/PARK8 and 
vacuolar protein sorting 35 ortholog (VPS35)] were since conclusively associated with 
autosomal dominant (AD) and four [parkin/PARK2, PTEN-induced kinase 1 
(PINK1)/PARK6, DJ-1/PARK7, ATP13A2/PARK9] with early-onset autosomal recessive 
(AR) PD (Corti et al., 2011; Vilariño-Güell et al., 2011; Zimprich et al., 2011). Recently, 
mutations in eukaryotic translation initiation factor 4-gamma (EIF4G1)/PARK18 was 




determine the frequency and pathogenicity of EIF4G1 variants, we screened all 31 EIF4G1 




We selected 251 index cases (>90% French) with dominant inheritance [≥2 affected 
individuals in 2 successive generations identified by examination of secondary cases (n=101) 
or family history (n=150)]. Most (>73%) had definite PD (Hughes et al., 1992): mean age at 
onset in 140 male and 111 female index patients was 50.2±12.0 years (range 14-86); age at 
examination, 58.2±11.8 years (range 24-87). Control subjects, 236 Europeans (134 males, 102 
females, mainly spouses) without family histories of PD, were examined at age 58.1±11.8 
(range 31-85). Patients with SNCA multiplications, SCA2 CAG repeat expansions and VPS35 
mutations were excluded. Since digenic parkinsonism has been observed (Dächsel et al., 
2006), subjects were screened for LRRK2 p.G2019S (most already reported, Lesage et al., 
2009). 
 
2.2 Molecular methods 
The local ethics committee approved the study. Peripheral blood was collected, with 
written informed consent, and DNA extracted from leukocytes by standard procedures. The 
31 EIF4G1 coding exons and exon-intron junctions were sequenced as reported, with 
modifications (Chartier-Harlin et al., 2011). Variant frequencies were compared in patients 
and controls with the chi-square test (significant at p<0.05). Mutation nomenclature follows 
HGVS recommendations: +1 is A of ATG initiation codon in NCBI Reference Sequences 
(RefSeq) NM_198241.2. Mutation taster (http://www.mutationtaster.org), Sorting Intolerant 
from Tolerant (SIFT) (http://sift.jcvi.org/) or Polymorphism Phenotyping (PolyPhen-2) were 






Sixty sequence variants (35 intronic, 25 exonic) were found (Tables 1, 2). Twelve 
coding variants, including six novel, were synonymous (five only detected in controls). We 
also identified four novel, rare non-synonymous amino acid substitutions or in-frame 
insertions/deletions (indels) (p.A433V/c.1298C>T, p.E465del/c.1384_1386delGAA, 
p.E462delInsGK/c.1384_1386insGAA, p.P446H/1337C>A) (Table 1); none affected protein 
function in silico. Segregation analysis was not possible except for p.E462delInsGK, found in 
two affected siblings. Of the 12 rare missense or indels variants, six were present exclusively 
in cases and three in controls, including two reportedly putative disease-causing mutations 
(Chartier-Harlin et al., 2011): p.G686C/c.2056G>C found in two isolated patients and 
p.R1197W/c.3589C>T in a healthy 46 year-old control (Table 1).  
Male patient FPD-832-1 carried LRRK2 p.G2019S in addition to EIF4G1 p.G686C. 
Diagnosed at age 58, his Hoehn and Yahr score, at age 68, was 2/5; his UPDRS III motor 
score, 41/132 “off” and 24 “on,” reflected a good L-dopa response; he had no cognitive 
impairment [Mini Mental State Examination (MMSE) =28/30]. Female patient FPD-252-13, 
with EIF4G1 p.G686C, had PD according to UK Brain Bank criteria (Hughes et al., 1992), 
onset at age 52, a Hoehn and Yahr score of 2/5, at age 67, excellent L-dopa response, peak-
dose dyskinesias, but no cognitive impairment (MMSE=29/30).  
Variants with minor allele frequencies (MAF) ≥0.05 (n=9) were tested for Hardy-
Weinberg equilibrium (HWE) and association with PD in patients and controls (Table 2). 
Two of them (rs939317 and rs1879244) deviated from equilibrium in the patient group with 
p-values of 0.01 and 0.02, respectively versus 0.31and 0.35 in the healthy control group. None 
of the polymorphic variants showed an association with PD in the case-control study, except 
for the rs9846954 variant (genotype, p=0.03; alleles, p=0.007; Table 2) that was not 






Linkage and candidate gene analysis identified the p.R1205H mutation in EIF4G1, 
encoding a component of the eIF4F translation initiation complex that regulates cell survival 
in response to stressors, in a large French family with AD late-onset PD and seven smaller 
families of various origins, probably resulting from an ancestral founder (Chartier-Harlin et 
al., 2011). Screening additional patients with parkinsonism and Lewy body disease identified 
four less frequent putatively disease-causing mutations, p.A502V, p.G686C, p.S1164R and 
p.R1197W, absent from ~4,000 controls, but their involvement in disease pathogenesis 
remains inconclusive, in absence of segregation analyses. The most frequently reported 
EIF4G1 mutation, p.R1205H, was not present in the 487 individuals tested here, nor 
p.A502V, but the rare p.G686C variant was found in two PD families, one with LRRK2 
p.G2019S, suggesting that EIF4G1 mutations are not a common cause of PD at least in our 
population; the p.R1197W variant however found in a control is probably a rare benign 
polymorphism. In our study, we identified three novel rare missense and indels variations, 
present only in cases but their pathogenicity remains to be proven in the absence of 
segregation data and deleterious effects predicted in silico. This result highlights the 
difficulties of interpreting the occurrence of rare missense variations in an isolated sporadic 
patient or in families that are too small to be informative in segregation analyses, even if they 
are not found in a large number of controls. 
As previously reported (Chartier-Harlin et al., 2011), no significant association with PD 
was found. Our cases with p.G686C mutations had idiopathic PD, good responses to L-DOPA 
and no dementia, consistent with the late-onset idiopathic Lewy body parkinsonism 
previously reported in EIF4G1 patient carriers.  
In conclusion, we do not provide conclusive evidence that the variants identified are 




very rare in the PD population. Large multi-center studies, as performed for the LRRK2 gene 
(Ross et al., 2011) are needed to determine the frequency and the pathogenicity of EIF4G1 in 
PD in diverse populations worldwide. So far, the evidence of its role remains inconclusive. 
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Table 1. Rare coding EIF4G1 gene variants (MAF<5%) detected in the 251AD PD index cases and 236 healthy controls.  
Location Accession N°. Nucleotide change
a
 Protein change 
Cases (frequency, %) 
(n=251) 
Healthy controls (frequency, %) 
(n=236) 
Exon10  c.720C>T p.I240I 0  1 HTZ (0.4) 
Exon10 rs16858632 c.932A>G p.Y311C 1 HTZ (0.4) 0 
Exon10  c.1298C>T p.A433V 1 HTZ (0.4) 0 
Exon10  c.1337C>A p.P446H 0 1 HTZ (0.4) 
Exon10  c.1384_1386delGAA p.E465del 1 HTZ (0.4) 0 
Exon10  c.1384_1386insGAA p.E462delInsGK 1 HTZ (0.4) 0 
Exon10 rs111659103 c.1413_1421del p.G472_A474del 9 HTZ (3.6) 9 HTZ (3.8) 
Exon12 rs111924994 c.1648G>C p.A550P 0 1 HTZ (0.4) 
Exon14  c.2028A>G p.T676T 0 1 HTZ (0.4) 
Exon14 rs112019125 c.2056G>T p.G686C 2 HTZ (0.8) 0 
Exon15 rs111396765 c.2149G>C p.A717P 1 HTZ (0.4) 0 
Exon15  c.2211C>T p.S737S 0 1 HTZ (0.4) 
Exon 20 rs112420733 c.2976A>G p.P992P 5 HTZ (2.0) 2 HTZ (0.8) 




Exon 25 rs35629949 c.3685C>G p.P1229A 2 HTZ (0.8) 4 HTZ (1.7) 
Exon 25 rs2230570 c.3698T>C p.L1233P 7 HTZ (2.8) 7 HTZ (3) 
Exon 29  c.4179G>T p.G1393G 0 1 HTZ (0.4) 
Exon 29 rs76779558 c.4251C>T p.V1417V 13 HTZ (5.2) 9 HTZ (3.8) 
Exon 30 rs111921843 c.4383C>T p.F1461F 2 HTZ (0.8) 6 HTZ (2.5) 
Exon 30 rs112718796 c.4386C>T p.D1462D 6 HTZ, 1 HMZ (2.8) 6 HTZ (2.5) 
Exon 32 rs11559218 c.4551C>T p.D1517D 0 6 HTZ (2.5) 
Exon 32  c.4572G>T p.A1524A 1 HTZ (0.4) 0 
Exon 33  c.4740A>G p.K1580K 0 1 HTZ (0.4) 
a
Human EIF4G1 cDNA sequence (RefSeq Accession number NM_198241.2) was used as the reference sequence.  
The A of the ATG translation initiation start codon represents nucleotide +1. 
Novel variations detected in this study are shown in bold. 




Table 2. Intronic and frequent exonic EIF4G1 gene variants (MAF≥5%) detected in the 251AD PD index cases and 236 healthy controls.  
Location Accession N°. Nucleotide change
a
 Protein  Genotypes  Minor allelic  HWE  
   change WT/HET/MUT frequency (%) (p-value) 
    Cases Controls Cases Controls Cases Controls 
Intron3  c.60+20_60+23del  248/3/0 229/7/0 0.60 1.48   
Intron8  c.631-36T>A  251/0/0 235/1/0 0 0.21   
Intron9  c.697+24C>T  250/1/0 236/0/0 0.20 0   
Intron9 rs114840884 c.697+50A>G  250/1/0 235/1/0 0.20 0.21   
Intron9 rs9846954 c.697+93A>T  169/73/9* 134/85/17* 18.1** 25.2** 0.75 0.49 
Intron9 rs4912537 c.698-101C>T  163/75/13 147/80/9 20.1 20.8 0.26 0.64 
Intron9  c.698-50G>A  251/0/0 235/1/0 0 0.21   
Intron9  c.698-10T>C  251/0/0 235/1/0 0 0.21   
Exon10 rs2178403 c.1294G>A  p.M432V 142/96/13 145/84/7  24.30 20.80 0.53 0.21 
Intron10 rs16858641 c.1519+46C>G  250/1/0 236/0/0 0.20 0   
Intron10 rs80195889 c.1520-22T>C  243/7/1 229/7/0 1.79 1.48   
Intron12  c.1796-3C>T  250/1/0 235/1/0 0.20 0.21   




Intron14 rs114075070 c.2089-28C>T  247/4/0 231/4/0 0.80 0.85   
Intron15  c.2275-71C>T  251/0/0 235/1/0 0 0.21   
Intron15 rs80174971 c.2275-69C>G  249/2/0 236/0/0 0.40 0   
Intron 16  c.2472+57G>T  250/1/0 236/0/0 0.20 0   
Intron 16 rs16858643 c.2473-18A>G  249/2/0 236/0/0 0.40 0   
Intron 18  c.2857-55G>T  251/0/0 235/1/0 0 0.21   
Intron 18 rs17818331 c.2857-38A>G  237/14/0 221/15/0 2.79 3.18   
Intron 19 rs114930389 c. 2962-53T>C  251/0/0 235/1/0 0 0.21   
Intron 21  c.3223-214G>A  251/0/0 235/1/0 0 0.21   
Intron 21 rs35606653 c.3223-120A>G  244/7/0 235/1/0 1.39 0.21   
Intron 21  c.3223-67A>G  251/0/0 235/1/0 0 0.21   
Intron 22 rs2293605 c.3325+16C>T  201/45/5 186/48/2 11.00 11.01 0.20 0.57 
Intron 22  c.3325+25G>A  250/1/0 236/0/0 0.20 0   
Intron 26 rs939317 c.3953+9A>G  152/95/4 140/87/9 20.52 22.25 0.01* 0.31 
Intron 26  cc.3953+32_3953+33del  250/1/0 236/0/0 0.20 0   




Intron 26 rs55772945 c.3953+312C>G  124/111/16 129/85/22  28.49 27.33 0.18 0.15 
Intron 26  c.3953+344G>A  250/1/0 235/1/0 0.20 0.21   
Intron 26 rs1879244 c.3954-64T>C  146/99/6 141/86/9 22.11 22.03 0.02* 0.35 
Exon 27 rs2230571 c.4005C>T p.H1335H 126/109/16 129/86/21 28.09 27.12 0.23 0.23 
Intron 27 rs115910779 c.4080-85G>A  243/8/0 227/9/0 1.59 1.91   
Intron 30  c.4395+12C>T  250/1/0 236/0/0 0.20 0   
Intron 32 rs62287502 c.4619-95G>T  230/20/1 217/19/0 4.38 4.03 0.44 0.52 
Intron 32  c.4619-13C>T  251/0/0 235/1/0 0 0.21   
a
Human EIF4G1 cDNA sequence (RefSeq Accession number NM_198241.2) was used as the reference sequence. The A of the ATG translation 
initiation start codon represents nucleotide +1. 
HET: heterozygote; HWE: Hardy Weinberg equilibrium; MAF: Minor Allele Frequency; MUT: mutated; WT: wild-type. 
Genotypic and allelic comparisons between patient and control groups: *p=<0.05; **p<0.01. 
 
